Fulton Bank N.A. reduced its holdings in AbbVie Inc. by 5.8% in Q4, selling 2,892 shares worth about $10.76 million. AbbVie faces mixed analyst views with price targets ranging from $230 to $299, and recent insider stock sales have decreased executive holdings. The company reported strong Q4 earnings beating estimates and raised its 2026 guidance, but faces competitive pressures from new drug approvals and generic entrants. AbbVie also announced a quarterly dividend with a 3.4% yield, maintaining appeal for dividend-focused investors despite recent stock volatility.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
